Skip to main content
SVBI logo

SVBI — Investor Relations & Filings

Ticker · 1786 ISIN · TW0001786002 TW Manufacturing
Open in API
Filings indexed 1,687 across all filing types
Latest filing 2019-03-08 Fund Information / Fact…
Country TW Taiwan
Listing TW 1786

About SVBI

www.scivision.com.tw

SciVision Biotech Inc. is a specialized developer and manufacturer of advanced medical devices, focusing on the research and production of hyaluronic acid (HA) products. The company leverages its proprietary Crosslinked Hyaluronic Acid Platform (CHAP) technology to create high-performance solutions across multiple medical disciplines. Its core product portfolio includes subcutaneous fillers for facial aesthetics, intra-articular injections for orthopedic joint care, anti-adhesion gels for surgical applications, and vesical instillation solutions for urological treatments. By integrating specialized R&D capabilities with precision manufacturing, SciVision Biotech provides medical-grade HA applications designed to improve patient outcomes in aesthetics and therapeutic recovery. The company is committed to scientific innovation and the expansion of its patented technology to meet diverse clinical needs in the global healthcare market.

Recent filings

Filing Released Lang Actions
108年2月營業收入
Fund Information / Factsheet Classification · 95% confidence The document is a summary report of monthly and cumulative operating revenue figures for a company named 科妍, presented in a tabular format with percentage changes and notes. It is very short (766 characters) and contains no detailed financial statements, management discussion, or comprehensive analysis. It does not appear to be a full Annual Report (10-K), Interim Report (IR), or Earnings Release (ER). It also does not contain any regulatory certifications, voting results, or management changes. The document is essentially a brief financial summary or factsheet of key revenue figures for a specific month and year (February 2019, 民國108年02月). Given the brevity and nature of the content, the best fitting category is Fund Information / Factsheet (FS), which covers brief summaries of key company facts and financials.
2019-03-08 Chinese
108年2月背書保證與資金貸與
Regulatory Filings Classification · 95% confidence The document is a brief financial disclosure from a listed company, 科妍, reporting on the status of fund loans and endorsement guarantees for the current and previous months, with amounts all zero. It contains tabular data but no detailed financial statements or analysis. The document length is very short (601 characters), and it appears to be a regulatory disclosure of financial status rather than a full report or announcement of a meeting or vote. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a typical regulatory compliance filing reporting specific financial information. Therefore, the best fitting category is Regulatory Filings (RNS).
2019-03-08 Chinese
108年02月內部人持股異動(事後)
Director's Dealing Classification · 95% confidence The document consists of detailed tables listing shareholdings of company insiders, including directors, supervisors, managers, and their family members. It provides data on stock types, quantities held at different times, increases and decreases in holdings, and other related information. The content is focused on insider share transactions and holdings rather than financial results, management changes, or other corporate events. There is no indication of a full financial report, earnings release, or meeting materials. The document is not a brief announcement but a detailed disclosure of insider shareholdings. This matches the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document length is sufficient and the content is consistent with insider shareholding disclosures.
2019-03-06 Chinese
108年02月董事會成員及持股
Director's Dealing Classification · 95% confidence The document is a detailed tabulation of shareholdings by company insiders, including directors, supervisors, and managers, showing their current and pledged shares. It lists individual names, titles, and share counts, focusing on insider shareholdings and related disclosures. There is no indication of financial statements, earnings data, meeting materials, or regulatory certifications. The content aligns with insider shareholding disclosures, which typically fall under Director's Dealing or Major Shareholding Notification categories. However, since it reports insider holdings without specific transactions or threshold crossings, it is best classified as a Director's Dealing report, which covers personal share transactions or holdings by company directors and executives. The document length is short (2708 characters), and it is a direct disclosure, not an announcement or summary. Therefore, the appropriate classification is DIRS with high confidence.
2019-03-06 Chinese
公告本公司國內第一次發行無擔保轉換公司債完成。
Capital/Financing Update Classification · 95% confidence The document is a short announcement (638 characters) from a company about the completion of its first domestic issuance of unsecured convertible bonds. It includes details such as the event date, company name, and confirmation that the funds have been fully collected and deposited. There is no financial statement, detailed analysis, or report content. The document is an update on a financing activity, specifically a capital raising event through bond issuance. Given the short length and nature of the content, it is not a full financial report but an announcement related to capital/financing update.
2019-02-27 Chinese
公告本公司國內第一次無擔保轉換公司債完成訂價
Capital/Financing Update Classification · 95% confidence The document is a short announcement from a company (科妍生物科技股份有限公司) about the pricing completion of its first domestic unsecured convertible bonds. It includes details such as the event date, company name, regulatory approval reference, and pricing basis. The document is brief (729 characters) and focuses on a financing activity (bond issuance and pricing). It does not contain financial statements or detailed financial analysis, nor is it a full report. It is an update on a capital raising event, fitting the Capital/Financing Update category. It is not a report publication announcement or regulatory filing since it provides substantive information about the financing event itself.
2019-02-20 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.